Back to clinical trials
RecruitingObservational
Real-World Patient Experience of Vimseltinib for the Treatment of Tenosynovial Giant Cell Tumor
NCT ID: NCT07075471Sponsor: Deciphera Pharmaceuticals, LLCLast updated: 2025-11-05
Summary
The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT. This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.
Outcome measures
Primary
Duration of Vimseltinib Treatment
Time frame: Baseline up to 12 months
Time to Discontinuation of Vimseltinib
Time frame: Baseline to Discontinuation (Estimated up to 12 months)
Eligibility criteria
Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria:
1. Diagnosis of TGCT according to medical records
2. Prescribed vimseltinib per the approved label requirements. Participants are eligible if either (A) the decision to receive vimseltinib has been made but treatment has not yet been initiated or (B) the decision to receive vimseltinib has been made and participant has received first dose of prescribed vimseltinib less than 6 months prior to study enrollment
3. Has provided informed consent and medical records release
Exclusion Criteria:
1. Participant has received any other systemic agent for the treatment of TGCT during the 6 months prior to starting treatment with vimseltinib
2. Participant has received the first dose of prescribed vimseltinib in the current treatment course more than 6 months before study enrollment
3. Participant is active in an interventional clinical trial of vimseltinib
Study locations (1)
Synexus Clinical Research, US INC
Wilmington, North Carolina, 28401
· Contact